Compounds > carbachol
Page last updated: 2024-11-07

carbachol and ER-Negative PR-Negative HER2-Negative Breast Cancer

carbachol has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Español, AJ1
Salem, A1
Di Bari, M1
Cristofaro, I1
Sanchez, Y1
Tata, AM1
Sales, ME1

Other Studies

1 other study available for carbachol and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
    PloS one, 2020, Volume: 15, Issue:9

    Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arecoline; ATP

2020